Bone Biologics is developing a differentiated, biologically active orthobiologic platform (NB-1, based on rhNELL-1) to improve spinal fusion outcomes in high-risk “hard-to-heal” patients, addressing a major gap in a $3B+ market. The post Strategic regeneration: Leveraging precision biologics and scalable innovation to transform spinal fusion appeared first on Digital Journal .